412 results
8-K
EX-99.1
ACORQ
Acorda Therapeutics Inc
17 Apr 24
Acorda Therapeutics Announces Delisting from Nasdaq
9:10am
research and development programs, or any other acquired or in-licensed programs; the occurrence of adverse safety events with our products; the outcome
8-K
EX-99.1
ACORQ
Acorda Therapeutics Inc
1 Apr 24
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
8:12pm
generally improves over time; the risk of unfavorable results from future studies of INBRIJA (levodopa inhalation powder) or from other research … and development programs, or any other acquired or in-licensed programs; the occurrence of adverse safety events with our products; the outcome (by judgment
8-K
EX-99.1
0vbmb
11 Jan 24
Termination of a Material Definitive Agreement
8:33am
8-K
EX-99.1
zbffkpyhqmmar ax8
13 Nov 23
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
4:16pm
8-K
EX-99.1
mmulbsi
8 Aug 23
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
4:12pm
8-K
EX-99.1
rn1 7qm3l
26 Jun 23
Other Events
4:30pm
8-K
EX-99.1
darark2564 c07
2 Jun 23
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
4:28pm
8-K
EX-99.1
tvg7hht rjauyios
31 May 23
Other Events
5:07pm
8-K
EX-99.1
fivnlfo
11 May 23
Acorda Therapeutics Reports First Quarter 2023 Financial Results
4:15pm
8-K
EX-99.1
5k601fjki61b53fnb
10 May 23
Other Events
8:00am
8-K
EX-99.1
1650tw
8 May 23
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
5:16pm
8-K
7k96a313hy8zbo4iho
23 Dec 22
Regulation FD Disclosure
8:49am